Mode
Text Size
Log in / Sign up

Semaglutide associated with 35.2% of weight loss as lean mass versus 26.2% with lifestyle interventionsNew analysis shows weight loss drugs and lifestyle changes affect muscle loss similarly

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider integrating resistance training to preserve muscle mass during weight loss.

This systematic review and meta-analysis examined the impact of incretin-based therapies on body composition in adults with overweight or obesity. The analysis included data from 15 782 participants. The intervention group received incretin-based therapies, which encompass GLP-1 receptor agonists and dual GLP-1/GIP agonists. The comparator group underwent intensive lifestyle interventions. The primary outcome measured was the absolute change in lean mass in kilograms and the proportion of total weight lost as lean mass. The study setting was not reported. Safety and tolerability data, including adverse events and discontinuations, were not reported in the source material. The follow-up duration was not reported.

The meta-analysis found that the proportion of total weight lost as lean mass with semaglutide was 35.2%. The 95% confidence interval for this estimate ranged from 31.5% to 38.9%. For tirzepatide, the proportion of total weight lost as lean mass was 25.4%, with a 95% confidence interval of 22.8% to 28.0%. Liraglutide was associated with a proportion of total weight lost as lean mass of 26.8%, with a 95% confidence interval of 23.1% to 30.5%. In the comparator group, intensive lifestyle interventions resulted in a proportion of total weight lost as lean mass of 26.2%. The 95% confidence interval for lifestyle interventions was 24.1% to 28.3%.

When comparing incretin agonists directly to lifestyle interventions, the analysis showed comparable proportional lean mass loss. The p-value for this comparison was 0.42. A separate analysis of lifestyle interventions combined with resistance training showed a proportion of total weight lost as lean mass of 17.5%. The 95% confidence interval for this combined approach was 14.2% to 20.8%. The source data did not provide absolute numbers for these outcomes.

Heterogeneity across the included studies was moderate, with an I-squared value of 68%. The certainty of evidence was evaluated using the GRADE framework. Funding sources and potential conflicts of interest were not reported. The study did not report specific adverse events, serious adverse events, or rates of discontinuation.

These findings suggest that while pharmacologic agents like semaglutide promote significant weight loss, a substantial portion of that loss may be lean mass. The data indicate that the proportion of weight lost as lean mass with semaglutide (35.2%) is numerically higher than with lifestyle interventions (26.2%), yet the comparison between incretin agonists and lifestyle interventions yielded a p-value of 0.42, suggesting comparable proportional lean mass loss in the aggregate analysis. However, the addition of resistance training to lifestyle interventions reduced the proportion of weight lost as lean mass to 17.5%.

Clinical implications highlight the importance of muscle preservation strategies. Muscle mass can be significantly preserved by integrating resistance training, adequate protein intake, and body composition monitoring into weight-loss treatment programs. This is particularly relevant given that the proportion of total weight lost as lean mass with lifestyle plus resistance training was 17.5%, which is lower than the proportions observed with pharmacologic monotherapy. The practice relevance emphasizes that treatment programs should not rely solely on weight reduction metrics without considering body composition.

Several questions remain unanswered. The specific mechanisms driving the differences in lean mass loss between agents are not detailed in the source. The long-term sustainability of these body composition changes was not reported. The impact of varying dosages or treatment durations on lean mass preservation was not reported. Furthermore, the lack of reported safety data limits the ability to fully assess the risk-benefit profile of these interventions regarding muscle loss. The moderate heterogeneity observed (I = 68%) suggests that study populations or protocols may vary significantly, which could influence the generalizability of the findings.

Losing weight is a major goal for many adults with overweight or obesity. However, losing weight often means losing both fat and muscle. Muscle loss can slow metabolism and make it harder to stay healthy. This new research helps people understand what happens to their muscle when they lose weight using different methods. It compares popular weight loss medicines with lifestyle changes like diet and exercise. The findings offer important context for patients choosing a treatment plan.

The researchers looked at data from 15,782 participants. They analyzed how much of the total weight lost was actually lean muscle versus fat. The study included three common weight loss medicines: semaglutide, tirzepatide, and liraglutide. It also looked at intensive lifestyle interventions. These interventions involved strict diet and exercise plans. The goal was to see if the medicines caused more muscle loss than lifestyle changes.

The results showed that the proportion of weight lost as lean mass was very similar across groups. For semaglutide, 35.2 percent of the weight lost was lean mass. Tirzepatide showed 25.4 percent. Liraglutide showed 26.8 percent. The intensive lifestyle interventions group showed 26.2 percent. When researchers compared the medicines directly to lifestyle interventions, they found no significant difference. The p-value was 0.42, which means the difference was not statistically significant. Essentially, the drugs did not cause more muscle loss than the lifestyle changes.

One group received lifestyle interventions plus resistance training. This group had a lower proportion of lean mass loss at 17.5 percent. This suggests that adding strength training to a weight loss plan can help preserve muscle. The study did not report specific safety data like adverse events or discontinuations. It also did not report funding sources or conflicts of interest. The certainty of the evidence was evaluated using the GRADE system.

The study has some limitations. There was moderate heterogeneity, with an I-squared value of 68 percent. This means the results varied quite a bit between the different studies included in the review. Because of this variation, the results should be interpreted with caution. This is a single meta-analysis, so it does not prove that every patient will have these exact results. Individual responses to weight loss treatments can vary widely.

For patients right now, this study suggests that muscle mass can be preserved by integrating resistance training into weight loss programs. It also highlights the importance of adequate protein intake and monitoring body composition. Patients should not assume that weight loss medicines automatically cause more muscle loss than diet and exercise. They should discuss their specific goals with a healthcare provider. A plan that includes strength training might be the best way to lose weight while keeping muscle.

What this means for you:
Weight loss drugs and lifestyle changes showed similar muscle loss; adding resistance training may help preserve muscle.

Study Details

Study typeMeta analysis
Sample sizen = 782
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
AIMS: To compare lean mass changes between incretin-based therapies (GLP-1 receptor agonists and dual GLP-1/GIP agonists) and intensive lifestyle interventions in adults with overweight or obesity, and to determine whether the proportion of total weight lost as lean mass differs between these treatment modalities. MATERIALS AND METHODS: PubMed, Embase, Cochrane CENTRAL, and Web of Science were searched from inception through 20 January 2026. Randomised controlled trials of semaglutide, tirzepatide, liraglutide or lifestyle interventions reporting body composition outcomes measured by dual-energy X-ray absorptiometry or magnetic resonance imaging were included. The co-primary outcomes were the absolute change in lean mass (kg) and the proportion of total weight loss attributable to lean mass. Data were pooled using random-effects models. Risk of bias was assessed using Cochrane RoB 2, and certainty of evidence was evaluated using GRADE. RESULTS: Twenty randomised controlled trials (RCTs) comprising 15 782 participants met inclusion criteria. Lean mass constituted 25%-39% of total weight lost with incretin agonists: semaglutide (35.2% [95% CI: 31.5-38.9]), tirzepatide (25.4% [22.8-28.0]) and liraglutide (26.8% [23.1-30.5]). Lifestyle interventions showed comparable proportional lean mass loss (26.2% [24.1-28.3]; p = 0.42 for comparison), while lifestyle plus resistance training demonstrated the most favourable profile (17.5% [14.2-20.8]). Heterogeneity was moderate (I = 68%). No publication bias was detected (Egger's test p = 0.23). CONCLUSIONS: Lean mass loss during significant weight reduction is substantial, and the proportion of weight lost as lean mass is broadly comparable between incretin-based pharmacotherapy and lifestyle interventions. Muscle mass can be significantly preserved by integrating resistance training, adequate protein intake, and body composition monitoring into weight-loss treatment programs.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.